Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read why MTSR stock is a Strong Buy.
6don MSN
We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...
Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates. The bank highlighted Metsera's (NASDAQ:MTSR) long-acting GLP-1RA asset ...
The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.
Metsera , Inc. (NASDAQ:MTSR), a pharmaceutical company with a market capitalization of $2.68 billion, has disclosed the approval of 2024 annual cash bonuses for its named executive officers ...
Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...
Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...
Metsera’s (NASDAQ:MTSR – Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of ...
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...
In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year ...
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...
In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $20 million in insider spending recently. As the stock market navigates ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results